The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
Irantzu Anzar(Oslo Cancer Cluster), Trevor Clancy(Inholland University of Applied Sciences), Ola Myklebost(Oslo University Hospital), Boris Simovski, Hugues Fontenelle(Oslo Cancer Cluster), Ioannis Vardaxis, Emily Z. Keung(The University of Texas MD Anderson Cancer Center), Pubudu Samarakoon(Cancer Registry of Norway), Richard Stratford, Melissa Burgess(University of Pittsburgh Medical Center), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Brandon Malone, Leonardo A. Meza‐Zepeda(University of Oslo)
Cited by 0
Related Papers
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2012|906
Depletion of Murine Intestinal Microbiota: Effects on Gut Mucosa and Epithelial Gene Expression
|PLoS ONE|2011|543
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
|Annals of Oncology|2020|232
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
|The Lancet Oncology|2016|213
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
|Clinical Cancer Research|2018|195